Skip to main content
SpringerLink
Log in

Der Wirkstoff Botulinumtoxin

  • Chapter
  • First Online:
Botulinumtoxin in der ästhetischen Dermatologie

Zusammenfassung

Botulinumtoxin A

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (2001) Working group on civilian biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070

    Article  CAS  Google Scholar 

  • Burgen AS, Dickens F, Zatman LJ (1949) The action of botulinum toxin on the neuro-muscular junction. J Physiol 109:10–24

    Article  CAS  Google Scholar 

  • Carruthers JD, Carruthers JA (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol Jan;8(1):17–21

    Google Scholar 

  • Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, Bernstein J, Marcus SM, Kumar S, Malecki J, Sobel J, Braden CR (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA Nov 22; 296(20):2476–2479

    Google Scholar 

  • Dailey RA, Philip A, Tardie G (2011) Long-term treatment of glabellar rhytides using onabotulinumtoxina. Dermatol Surg Jul;37(7):918–28. https://doi.org/10.1111/j.1524-4725.2011.02024.x. Epub 2011 May 16

  • D’Epiro S, Macaluso L, Salvi M, Luci C, Mattozzi C, Marzocca F, Salvo V, Scarnò M1, Calvieri S1, Richetta A (2014) Safety and prolonged efficacy of Botulin toxin A in primary hyperhidrosis. Clin Ter Nov–Dec;165(6):e395–400. https://doi.org/10.7417/ct.2014.1780

  • DGBT. https://www.dgbt.de

  • Dover N, Barash JR, Hill KK, Xie G, Arnon SS (2014) Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis Jan 15;209(2):192–202. https://doi.org/10.1093/infdis/jit450. Epub 2013 Oct 7

  • Dressler D (2003) Nervenarzt 74:1098–1104. https://doi.org/10.1007/s00115-003-1611-5

  • Dressler D et al (2010) Antibody-induced failure of Botulinum toxin type A therapy in cosmetic indications. Dermatol Surg 36:2182–2187

    Google Scholar 

  • Dressler D et al (2014) Safety aspects of incobotulinumtoxin A high-dose therapy. J Neural Transm. https://doi.org/10.1007/s00702-014-1252-9

    Article  PubMed  Google Scholar 

  • Friesecke I et al (Hrsg) (2007) Virale Hämorrhagische Fieber (VHF). In: Handbuch „Biologische Gefahren II – Entscheidungshilfen zu medizinisch angemessenen Vorgehensweisen in einer B-Gefahrenlage“. BBK, RKI, Bonn

    Google Scholar 

  • Halpin JL, Hill K, Johnson SL, Bruce DC, Shirey TB, Dykes JK, Lúquez C (2017) Finished whole-genome sequence of Clostridium argentinense producing Botulinum Neurotoxin Type G. Genome Announc May 25;5(21):e00380–17. https://doi.org/10.1128/genomea.00380-17. PMID:28546482

  • Hefter H (2014) Notwendigkeit einer statistisch präzissen Analyse der Bildungswahrscheinlichkeit neutralisiernender Antikörper in der Botulinumtoxin-Therapie. Thieme Drug Report 7(8):8–9

    Google Scholar 

  • Hefter H et al (2012) Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinum toxin type A preparation free of complexing proteins – a single cohort 4-year follow-up study. BMJ open 2(4):e000646. https://doi.org/10.1136/bmjopen-2011-000646

  • Heinen F, Wissel J, Philipsen A et al (1997) Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 28:307–313

    Google Scholar 

  • Heinen F, Schroeder AS, Fietzek U et al (2006) When it comes to botulinum toxin, children and adults are not the same: Multimuscle option for children with cerebral palsy. Mov Disord Nov;21(11):2029–2030

    Google Scholar 

  • Hunt T, Clarke K (2008) Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J Am Acad Dermatol 58(3):517–518

    Google Scholar 

  • Imhof M, Podda M, Sommer B (2013) AWMF-Leitlinie „Ästh Btx“/ S1 guideline aesthetic botulinum toxin therapy. German Society for Dermatosurgery; German Society for Dermatology. J Dtsch Dermatol Ges Oct;11(10):e1–13. https://doi.org/10.1111/ddg.12195

  • ISAPS. Demand for cosmetic procedures around the world. International Society of Aesthetic Plastic Surgeons; Press Release, 2017. https://www.isaps.org/medical-professionals/isaps-global-statistics/. Zugegriffen: Oct 2018

  • Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324:1186–1194

    Google Scholar 

  • Kammerer RA, Benoit RM (2014) Botulinum neurotoxins: new questions arising from structural biology. Trends Biochem Sci Nov;39(11):517–526. https://doi.org/10.1016/j.tibs.2014.08.009

  • King LA, Popoff MR, Mazuet C et al (2010) Infant botulism in France, 1991–2009. Arch Pediatr 17:1288–1292

    Google Scholar 

  • Naumann M, Boo LM, Ackerman AH, Gallagher CJ (2013) Immunogenicity of botulinum toxins. J Neural Transm Feb;120(2):275–290. https://doi.org/10.1007/s00702-012-0893-9. Epub 2012 Sep 25. Review

  • Pickett A, Mewies M (2009) Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol 61(1):149–150

    Google Scholar 

  • Rappl T, Parvizi D, Friedl H, Wiedner M, May S, Kranzelbinder B, Wurzer P, Hellbom B (2013) Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol Sep 24;6:211–219. https://doi.org/10.2147/CCID.S41537

  • Reichel G (2002) Therapieleitfaden Spastik – Dystonie, 4. Aufl. UniMed-Verlag, Bremen

    Google Scholar 

  • RKI-Ratgeber Botulisums, Robert Koch Institut. https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Botulismus.html

  • Rossetto O, Megighian A, Scorzeto M, Montecucco C (2013) Botulinum neurotoxins. Toxicon. Jun 1;67:31–6. https://doi.org/10.1016/j.toxicon.2013.01.017

  • Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol Aug;12(8):535–549. https://doi.org/10.1038/nrmicro3295. Epub 2014 Jun 30

  • Russmann H (2003) Toxine Bundesgesundheitsbl – Gesundheitsforsch -Gesundheitsschutz 46:989–996

    Google Scholar 

  • Santamato A et al (2013) Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm 120:469–476

    Google Scholar 

  • Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev Mar;56(1):80–99. Review

    Google Scholar 

  • Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044–1049

    Google Scholar 

  • Scott AB, Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3(4):333–335

    Google Scholar 

  • Sommer B, Bergfeld D, Sattler G et al (Hrsg) (2015) Botulinumtoxin in der ästhetischen Medizin, 5., aktual. Aufl. Thieme, Stuttgart. https://doi.org/10.1055/b-003-128226

  • Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet Aug 2;2(8501):245–247

    Google Scholar 

  • van Ermengen E (1897). Über ein neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektkr 26:1–56

    Google Scholar 

  • Wissel J (2010) Botulinum-Neurotoxin in der Behandlung der Spastizität im Erwachsenenalter. Der Nervenarzt 82(4):481–495

    Article  Google Scholar 

  • Yamauchi PS, Lowe NJ (2004) Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol Jan–Feb;22(1):34–39

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatologie am Luegplatz, Düsseldorf, Deutschland

    Peter Arne Gerber

  2. Privatpraxis Dr. Hilton & Partner, Düsseldorf, Deutschland

    Said Hilton

Authors
  1. Peter Arne Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Said Hilton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Arne Gerber .

Editor information

Editors and Affiliations

  1. Privatpraxis Dr. Hilton & Partner, Düsseldorf, Germany

    Said Hilton

  2. Dermatologie am Luegplatz, Düsseldorf, Germany

    Peter Arne Gerber

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gerber, P.A., Hilton, S. (2020). Der Wirkstoff Botulinumtoxin. In: Hilton, S., Gerber, P.A. (eds) Botulinumtoxin in der ästhetischen Dermatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-58953-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-58953-3_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-58952-6

  • Online ISBN: 978-3-662-58953-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation